More about post-transplant cyclophosphamide in haploidentical grafts: full or reduced doses?
| Autor: | Moisés Manuel Gallardo-Pérez, César Homero Gutiérrez-Aguirre, Juan Carlos Olivares-Gazca, Guillermo José Ruiz-Argüelles |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Hematology, Vol 29, Iss 1 (2024) |
| Druh dokumentu: | article |
| ISSN: | 16078454 1607-8454 |
| DOI: | 10.1080/16078454.2024.2313357 |
| Popis: | ABSTRACTHaploidentical hematopoietic can be conducted on an outpatient basis but the two main reasons to accept into the hospital a patient in this setting are complications of the hematological toxicity and/or the cytokine-release syndrome. With the aim of reducing the post-transplant cyclophosphamide-dependent toxicity without compromising its effectivity, attempts to reduce the dose of post-transplant cyclophosphamide have been made: Decreases from the conventional total dose of post-transplant cyclophosphamide (100 mg/Kg) have been explored worldwide, showing that decreasing the total dose to even 50 mg/Kg significantly decreases the toxicity of the procedure without compromising its efficacy, safety and results. We present here the salient data of the attempts to diminish the doses of post-transplant cyclophosphamide which have been done and published worldwide, information that suggests that the conventional doses of post-transplant cyclophosphamide can be significantly reduced thus decreasing the toxicity, without compromising the effectiveness of the procedure, mainly the development of graft versus host disease. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|